At its 2026 annual meeting on June 30, 2026, RenovoRx, Inc. stockholders approved an amendment to the Amended and Restated 2021 Omnibus Equity Incentive Plan to add 2,000,000 shares of common stock, representing 4.4% of total issued and outstanding shares, to the pool available for issuance. Stockholders also elected six directors for one-year terms and ratified the appointment of Frank, Rimerman + Co. LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The company is a biotechnology firm that develops medical devices for the delivery of therapeutics.
